Ardelyx Inc. Stock
€4.35
Your prediction
Ardelyx Inc. Stock
Ardelyx, Inc. is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines aimed at treating kidney and cardiovascular diseases. The company uses a unique approach to drug discovery, developing therapeutics that target ion channels and transporters, which play a critical role in regulating activities in the body. Ardelyx's lead product candidate, tenapanor, is being studied for the treatment of conditions such as hyperphosphatemia in patients with chronic kidney disease, irritable bowel syndrome with constipation, and diverticulosis. The company is listed on the NASDAQ exchange under the ticker symbol ARDX.
Pros and Cons of Ardelyx Inc. in the next few years
Pros
Cons
Performance of Ardelyx Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ardelyx Inc. | -2.140% | -4.963% | -22.486% | -19.886% | -12.447% | 172.198% | -10.995% |
| Krystal Biotech | -1.590% | 2.577% | 27.287% | -1.256% | 3.285% | 119.860% | - |
| Evolus Inc | -1.890% | 1.961% | -18.750% | -65.101% | -50.476% | -39.884% | 27.921% |
| Champions Oncology Inc | 0.930% | 0.000% | -3.571% | 28.571% | 13.445% | -28.947% | -31.210% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When examining the financials of Ardelyx, a player in the Biotechnology and Medical Research field, the overall impression reveals both challenges and potential opportunities. A deep dive into the company’s financial reports, including balance sheets, cash flow statements, and income statements, highlights a narrative of struggle in terms of profitability and operational efficiency. High research and development expenses accompany fluctuating revenues, while significant investment in growth hints at a potential future payoff if strategic plays materialize.
Pros of Ardelyx Financials
Positive Revenue Growth: The company recorded a quarterly revenue growth of approximately 3.05% year-over-year. This marked improvement signals that Ardelyx is gradually moving in the right direction, potentially appealing to investors seeking companies with growth trajectories in the competitive biotech landscape.
News
Ardelyx Q2 Revenue Jumps 33%
Ardelyx (NASDAQ:ARDX), a biopharmaceutical company focused on gastrointestinal and cardiorenal therapeutics, reported its second quarter 2025 earnings on August 4, 2025. The headline news was a
